01
Glioblastoma and other gliomas — a hard, immunosuppressed CNS setting where neoantigen vaccines are being tested as early intervention.
[NOT_YET_RECRUITING · PHASE1 · Shenzhen Geno-Immune Medical Institute] This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generat…
This week’s BioPharm Brief covers positive phase 3 melanoma results for Merck and Moderna’s individualized neoantigen therapy, a personalized cancer vaccine manufacturing platform entering clinical use, and a new brain-penetrant antibody approach for glioblastoma. Welcome to The …
A single-arm phase Ib trial of ZSNeo-DC, a personalized neoantigen-pulsed autologous dendritic cell therapy, showed good tolerability in newly-diagnosed glioblastoma patients. The treatment was well-tolerated with predominantly grade 1 or 2 adverse events, and secondary endpoints revealed a median progression-free survival of 16.2 months. This data supports the clinical viability of DC-based personalized vaccines as an adjuvant to standard radio-chemotherapy.
One of the primary factors in the development of cancer is the accumulation of genetic mutations. Some of these genetic mutations result in the emergence of unique antigens called neoantigens. These neoantigens are perceived as non-self by T cells, making them prime targets for c…
A review of glioblastoma immunobiology highlights a critical disconnect between murine models and human tumors: patient GBM is enriched for clonally expanded granzyme K+ T cells, whereas standard mouse models show exhausted T cells. This distinction suggests that current preclinical models may misrepresent the targetable neoantigen landscape. The authors argue that harnessing tumor-selective T cells via neoantigen vaccines or adoptive transfer requires a refined focus on these specific human TIL profiles.
Researchers Zhang, Chi, Liu, and colleagues published phase Ib results in Nature Communications for a personalized neoantigen-pulsed autologous dendritic cell therapy in newly diagnosed glioblastoma. The approach isolates patient dendritic cells, pulses them with tumor-specific neoantigens, and reintroduces them to activate cytotoxic T-cells against the heterogeneous tumor. This represents a direct clinical validation of personalized DC vaccine strategies for an aggressive brain cancer with limited treatment options.
GT Biopharma’s GNOS-PV01, a personalized DNA vaccine targeting patient-specific mutations in MGMT-unmethylated glioblastoma, is being evaluated in a Phase 1 study published in Nature Cancer. The trial utilizes multi-regional tumor sampling to address high heterogeneity, aiming to induce immune responses against dozens of neoantigens rather than single targets. This approach addresses the lack of efficacy seen with prior immunotherapies in this aggressive cancer subtype.
Beijing YSCell Biotech is launching an investigator-initiated, open-label Phase 1 trial for YS247, a tumor neoantigen-pulsed autologous dendritic cell injection for recurrent or progressive glioblastoma. The study employs a '3+3' dose-escalation design across three cohorts to assess safety, tolerability, and preliminary efficacy. Patients will receive subcutaneous injections every two weeks for eight doses.